NCT04379635 2026-03-18
Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)
BeOne Medicines
Phase 3 Active not recruiting
BeOne Medicines
Novartis
BeOne Medicines
BeOne Medicines
Stichting Hemato-Oncologie voor Volwassenen Nederland
Jazz Pharmaceuticals
Shanghai Jiao Tong University School of Medicine
BeOne Medicines
BeOne Medicines
Indaptus Therapeutics, Inc